Elon Musk discusses his sporadic use of ketamine under medical supervision to cope with negative mental states, emphasizing its positive impact on his well-being and clarifying that he remains sober during his social media activities. Musk's candidness about his ketamine use sparks mixed reactions, but he maintains that it doesn't affect his executive abilities or Tesla's value, while also addressing the broader conversation on mental health and psychoactive substance use in society.
Elon Musk, the well-known innovator and CEO of Tesla, often shares his thoughts on social media, sparking wide discussions. In a recent interview with Don Lemon, Musk discussed his experiences with ketamine, highlighting its positive impact on his well-being. Additionally, he assured that he remains sober during his late-night social media activities.
For more news like this, along with all the latest in legalization, research, and lifestyle, download our free cannabis news app.
During the conversation with Lemon, Musk confessed that ketamine helps him deal with negative mental states, such as depression. His use of this substance, he claims, occurs under medical supervision and is sporadic, every two weeks. According to Musk, this approach positively affects his ability to cope with emotional challenges.
“There are moments when I have something like… a negative chemical state in my brain, probably depression, that isn’t related to any negative news, and ketamine helps break out of the negative mood,” Musk told Lemon, as quoted by CNN.com.
Musk’s disclosure of his stance on ketamine has met with mixed reactions, both in the media and among investors. Despite speculation, Musk emphasized that his executive abilities and impact on Tesla’s value for shareholders remain unshaken. The value of Tesla, he says, speaks for itself, suggesting that his stress management methods should not be a concern for investors.
Musk also assured that he is sober during his famous late-night social media sessions. His posts often stir controversy, but he claims they are not the result of psychoactive substances. Musk also expressed frustration with the reaction to his management of the X platform, emphasizing that the criticism regarding content on the platform is exaggerated.
The interview also revealed tensions between Musk and Lemon, particularly in the context of free speech and content management on the X platform. Musk emphasized his commitment to creating an open space for discussion, even though his approach has drawn criticism and controversy.
“Regular drug use has moved from after-hours activity directly into corporate culture, leaving boards and business leaders to grapple with the responsibility for employees who often use them. At the forefront are tech managers and workers who see psychedelics and similar substances, including psilocybin, ketamine, and LSD, as gateways to business breakthroughs,” The Wall Street Journal reported last year, in an article about Musk’s known use of ketamine.
Elon Musk continues to provoke public discussions, not only about technology and innovation but also about his personal life and mental health. His openness about using ketamine and his approach to sobriety during social media activities shed light on his character, as well as broader societal trends regarding mental health and psychoactive substances. Despite controversies, Musk remains one of the most influential figures in the tech world, and his decisions and statements will continue to attract interest.
His approach to managing stress and depression with ketamine may serve as a reference point for discussions on alternative treatments for mental disorders. However, it’s important to remember that such therapies should be conducted under strict medical supervision and with appropriate caution. Musk emphasizes that his experiences should not be generalized, and each case requires individual assessment.
—
(Featured image by Daniel Oberhaus (CC BY 2.0) via Flickr)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Fakty Konopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The Superior Court of Justice in Brazil has legalized the cultivation, processing, and sale of…
Poland has classified medical cannabis as a high-risk substance (Group I-N) alongside heroin and fentanyl.…
The Australian Senate has rejected the Legalising Cannabis Bill 2023, which proposed a national framework…
The Fijian government is drafting legislation after public consultations to establish a transparent, inclusive framework…
A Leafwell study found chronic pain as the top condition treated with medical cannabis, although…
A survey found that women comprise 61% of home cannabis growers, marking a diversion from…